A reduced intensity conditioning regimen of fludarabine, cyclophosphamide, antithymocyte globulin, plus 2 Gy TBI facilitates successful hematopoietic cell engraftment in an adult with dyskeratosis congenita
Dyskeratosis congenita (DKC), also known as Zinsser --Engman --Cole syndrome, is a relatively rare, inherited form of progressive BM failure (BMF) syndrome characterized by the triad of reticulated skin pigmentation abnormalities, nail dystrophy and oral leukoplakia. 1 Patients with DKC and associated BMF, generally, do not respond to immunosuppressive therapy(ies) and are at higher risks of increased morbidity and mortality associated with allogeneic hematopoietic cell transplantation (allo-HCT), due to underlying organ impairment, particularly when using myeloablative doses of chemotherapy or chemoradiotherapy. 2, 3 Published literature with regard to effective conditioning regimen(s) for allo-HCT for patients with DKC is limited to single case reports or small case series. 4 --7 Accordingly, the optimal allo-HCT preparative regimen to be offered to patients with DKC remains unknown.
We describe a 27-year-old man who was diagnosed with DKC at the age of 15 after developing nail dystrophy, tongue ulcers, periorbital redness with telengectasias and hypopigmented skin lesions. Medical evaluation also noted marked growth retardation. A complete blood count showed mild pancytopenia (WBC ¼ 3.0 Â 10 3 /mL, hemoglobin ¼ 12.0 g/dL, platelet count ¼ 80 000/mL), but without any associated clinical symptomatology. Mutational analysis revealed a nucleotide transition of C to T (1150 C-T) resulting in an amino-acid substitution 353 Ala-Val in the DKC1 gene. The patient was relatively stable, from the hematological standpoint, until December 2010 when he developed worsening pancytopenia and required frequent hospitalizations for febrile neutropenia and packed RBCs (PRBC) and platelet transfusions. At the time, his complete blood count showed a WBC ¼ 1.7 Â 10 3 /mL, hemoglobin ¼ 7.6 g/dL and a platelet count ¼ 22 000/mL. BM aspirate and biopsy examination showed severe marrow hypocellularity (1%) with normal male karyotype. Radiological evaluation revealed severe atrophy of the right hepatic lobe with compensatory hypertrophy of the left and caudate lobes with associated findings suggestive of liver cirrhosis. There were multiple esophageal and gastroesophageal varices and splenomegaly, suggesting portal hypertension. He failed to respond to a trial of danazol. In February 2011, he underwent an allo-HCT using G-CSF-mobilized PBSC from his 10/10 (A, B, C, DRB1, DQ) HLAmatched brother following a preparative regimen consisting of i.v. fludarabine 30 mg/m 2 /day on days À6, À5, À4 and À3, CY 300 mg/m 2 /day on days À6, À5, À4 and À3, and antithymocyte globulin (Thymoglobulin, Genzyme, USA) 3.75 mg/kg/day on days À4 and À3 plus TBI of 2 Gy on day À1 as previously reported by Bacigalupo et al. 8 for patients with aplastic anemia. TBI was delivered in the supine position using lateral fields with the arms lying on the sides to provide partial lung shielding. GVHD prophylaxis consisted of cyclosporine (started on day À3 at 3 mg/kg/day in two divided doses subsequently tapered to therapeutic target levels between 200 --300 ng/mL) plus mycophenolate mofetil (750 mg orally twice daily started on day þ 1 until day þ 60). Neutrophil and platelet engraftment occurred on days þ 21 and þ 13, respectively. Donor chimerism measured by unsorted BM by STR/PCR on day þ 100 and þ 242 post transplantation showed 95% and 96% donor cells, respectively. In addition, BM biopsy results at days þ 100 and þ 242 showed 10% and 45% marrow cellularity, respectively, with adequate trilineage differentiation and maturation. His post-transplant course has been complicated by CMV reactivation treated successfully with anti-CMV therapy. Similarly, on day þ 71, he developed EBV reactivation, without associated disease treated successfully with weekly rituximab 375 mg/m 2 Â 6 doses. On day þ 115, he developed chronic GVHD of the skin (biopsy proven) and clinical findings suggestive of bronchiolitis obliterans, requiring bilevel positive airway pressure and treated with methylprednisolone plus mycophenolate mofetil. At the time of this report, the patient is doing well on day þ 284 post allogeneic HCT.
This case illustrates that using a reduced intensity conditioning (RIC) regimen of fludarabine, CY, antithymocyte globulin, plus 2 Gy TBI is feasible and facilitates successful hematopoietic cell engraftment in an adult with DKC. Introduction of fludarabine as an integral component of RIC regimens for allo-HCT, due to its strong T-cell immunosuppressive effect, represents an ideal option for RIC allo-HCT in patients with BMF syndromes, such as DKC or others, where myeloablative doses of chemotherapy or chemoradiotherapy are not necessary for disease eradication. In addition, as suggested by Dietz et al. 5 designing a successful RIC allo-HCT preparative regimen for patients with DKC and BMF requires incorporation of immunosuppressive agents such as fludarabine, reducing the dose of CY to avoid organ toxicity, and use of lowdose TBI, among others. As patients with DKC are at higher risk of developing organ impairment, such as pulmonary fibrosis and/or liver dysfunction due to their disease, it is imperative to exclude agents known to be associated with significant toxicity to these organs. 5 In our particular case, we opted to add a low-dose of TBI (2 Gy) because of its added immunosuppressive potential, and relatively low toxicity, to further reduce the risk of developing graft failure. For instance, MacMillan et al. 9 has shown that low-dose TBI (3 Gy) as part of conditioning regimens for patients with BMF syndromes, namely Fanconi anemia, results in consistent engraftment and improved outcomes when compared with patients who received higher doses of TBI or no TBI. In our case the patient tolerated 2 Gy TBI without pertinent toxicity in the acute setting, but it should be noted that this may not be applicable to all cases of DKC as some patients may not be able to tolerate TBI even at such low doses. In addition, consistent with published literature regarding administration of rabbit ATG in the setting of in vivo T-cell-depleted allo-HCT, our patient developed EBV reactivation for which we opted preemptive treatment with rituximab as previously described.
These patients are likely to benefit from early detection (and perhaps early treatment with rituximab) of EBV reactivation, especially in the face of a continuous rise in EBV DNA titers which generally leads to imminent disease in the setting of relatively prolonged T-cell depletion, as with this regimen. Although longer follow-up is needed to determine whether long-term toxicity is also improved with this regimen, post-transplant outcomes observed thus far in our patient are very encouraging and noteworthy.
Despite significant strides noted with introduction of RIC allo-HCT strategies for DKC or other BMF syndromes, large cooperative prospective trials aimed at further optimizing efficacy and safety of such regimens coupled with implementation of effective longterm surveillance strategies for serious infections or organ impairment, in light of unusually high risk for development of late complications, in these patients are critically needed.
